eptifibatide (integrilin) Report issue

Biologics Peptide Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Eptifibatide is a platelet aggregation inhibitor - an anti-coagulant that selectively blocks the platelet glycoprotein IIb/IIIa receptor. It is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake. It belongs to the class of the so called arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner. It is used for treatment of myocardial infarction and acute coronary syndrome.   NCATS

Chemistry

  • SMILES: NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CNC4=C3C=CC=C4)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O
  • InChIKey: CZKPOZZJODAYPZ-LROMGURASA-N
  • Mol. Mass: 831.962
  • ALogP: -1.84
  • ChEMBL Molecule:
    eptifibatide  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0001 - $899.3000

Australia

$74.9715 - $204.3381
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

eftifibatide | epifibatide | epifibratide | eptifibatide | integrelin | integrilin | intrifiban

Organizations (49)

Research & Development (31)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (19)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (1)


 

Acute Coronary Syndrome (approved 1999)

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Acute Coronary Syndrome (Phase 3)

Anemia, Sickle Cell (Phase 1/Phase 2)

Angina, Unstable (Phase 2)

Angioplasty (Phase 4)

Brain Infarction (Phase 2)

Cardiovascular Diseases (Phase 3)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 2)

Ischemic Stroke (Phase 3)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 3)

Non-ST Elevated Myocardial Infarction (Phase 4)

Pneumonia (Phase 2)

Shock, Septic (Phase 2)

ST Elevation Myocardial Infarction (Phase 2)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 28
  • # of Trial Organizations: 31

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue